Vulnerability to infections and secondary immunodeficiencies in patients with non-Hodgkin's lymphomas starting anti-CD20 antibody containing therapies
Compared to the period before receiving CD20CT serum IgG levels and T-helper cells decreased and patients suffered from increased infection rates. Immune monitoring is only performed in a minority of patients.
Authors
- Karl Verpoort
- RUDOLF WEIDE
- Achim Rothe (ORCID: https://orcid.org/0000-0003-1047-5694)
- Miriam Gärtner
- U. Vehling-Kaiser
- Johannes Mohm
- Stefan Feiten (ORCID: https://orcid.org/0000-0003-4737-7393)
- Helmut Forstbauer (ORCID: https://orcid.org/0000-0001-6602-7562)
- J. Lipke
- Stefan Fuxius
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1159/000551018
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00